|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2008-7-14
|
|
pubmed:abstractText |
Hammerhead ribozymes were designed to target mRNA of several essential herpes simplex virus type 1 (HSV-1) genes. A ribozyme specific for the late gene U(L)20 was packaged in an adenovirus vector (Ad-U(L)20 Rz) and evaluated for its capacity to inhibit the viral replication of several HSV-1 strains, including that of the wild-type HSV-1 (17syn+ and KOS) and several acycloguanosine-resistant strains (PAAr5, tkLTRZ1, and ACGr4) in tissue culture. The Ad-U(L)20 Rz was also tested for its ability to block an HSV-1 infection, using the mouse footpad model. Mouse footpads were treated with either the Ad-U(L)20 Rz or an adenoviral vector expressing green fluorescent protein (Ad-GFP) and then infected immediately thereafter with 10(4) PFU of HSV-1 strain 17syn+. Ad-U(L)20 ribozyme treatment consistently led to a 90% rate of protection for mice from lethal HSV-1 infection, while the survival rate in the control groups was less than 45%. Consistent with this protective effect, treatment with the Ad-U(L)20 Rz reduced the viral DNA load in the feet, the dorsal root ganglia, and the spinal cord relative to that of the Ad-GFP-treated animals. This study suggests that ribozymes targeting essential genes of the late kinetic class may represent a new therapeutic strategy for inhibiting HSV infection.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-10423678,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-10639314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-10800713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-10966788,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-11188989,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-11812839,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-11836397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-11883079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-12512303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-12824337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-1333128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-15017052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-15113914,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-15507638,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-15956979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-16306938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-16388859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-16490506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-17083931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-1719228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-1849972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-3018124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-4352373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-6246531,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-7793062,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-7831780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-7933124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-8106660,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-8422962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-9032314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-9188641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18508896-9501052
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1098-5514
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7467-74
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18508896-Adenoviridae,
pubmed-meshheading:18508896-Animals,
pubmed-meshheading:18508896-Antiviral Agents,
pubmed-meshheading:18508896-DNA, Viral,
pubmed-meshheading:18508896-Foot,
pubmed-meshheading:18508896-Ganglia, Spinal,
pubmed-meshheading:18508896-Gene Therapy,
pubmed-meshheading:18508896-Genetic Vectors,
pubmed-meshheading:18508896-Herpes Simplex,
pubmed-meshheading:18508896-Herpesvirus 1, Human,
pubmed-meshheading:18508896-Kinetics,
pubmed-meshheading:18508896-Mice,
pubmed-meshheading:18508896-RNA, Catalytic,
pubmed-meshheading:18508896-Spinal Cord,
pubmed-meshheading:18508896-Survival Analysis,
pubmed-meshheading:18508896-Transduction, Genetic,
pubmed-meshheading:18508896-Viral Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Reduction in severity of a herpes simplex virus type 1 murine infection by treatment with a ribozyme targeting the UL20 gene RNA.
|
|
pubmed:affiliation |
Department of Molecular Genetics and Microbiology, Box 100266, University of Florida College of Medicine, Gainesville, FL 32610-0266, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
